UNSPSC 51283944: Sulfaclomide

This classification denotes a sulfonamide anti-infective agent with the molecular formula C12H13ClN4O2S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier AXA8K5U95M, chemically known as 4-amino-n-(5-chloro-2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide but more generally known as sulfaclomide, which bears U.S. National Institutes of Health Compound Identifier 71168. The European Medicines Agency schedules Sulfaclomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10691MIG.

The term SULFACLOMIDE is an International Non-Proprietary Name. SULFACLOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=C(C(=NC(=N1)C)NS(=O)(=O)C2=CC=C(C=C2)N)CL.

UNSPSC 51283944 Sulfaclomide, a Commodity code, shows minimal recent state and local procurement activity directly aligned with its nominal scope. The one recent opportunity explicitly tagged to this code—Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023)—solicits naloxone and harm-reduction equipment rather than sulfaclomide, a sulfonamide antibiotic. The county seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, under an IFB with a two-year initial term and one-year renewal option. Vendors must provide unit costs, comply with drug-free workplace and E-Verify requirements, and maintain workers' compensation, commercial general liability, and professional liability insurance; the contract is potentially funded through FEMA and subject to federal environmental compliance reviews.

The remaining three opportunities in the recent activity block—Texas HHS's RFI on direct-to-manufacturer pharmacy programs, Tampa's IFB for medical and first aid supplies (estimated $700,000, awarded under SLBE set-aside with a 5 percent bid discount, due March 13, 2026), and Minnesota MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026, through authorized wholesalers)—do not involve sulfaclomide and appear to have been tagged to this code in error. The code shows no demonstrated state or local demand for sulfaclomide itself in the recent record. Firms evaluating this code should assess whether sulfaclomide procurement by state and local health departments, correctional facilities, or public hospitals represents a viable pursuit, as current market signals are absent.